ixoberogene soroparvovec

AXP000258.1 · Viral vector gene therapy

Platform
AAV.7m8 vector
Originator
Adverum Biotechnologies
Sponsor
Adverum Biotechnologies

Names

NameTypeSource
ixoberogene soroparvovecpreferred namecurator
ixo-vecsynonymctgov
ADVM-022former codectgov

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus (7m8 capsid variant)
Strain
AAV.7m8
Replication
non replicating
Modifications
7m8 peptide-insertion capsid variant
Transgenes
aflibercept
Route
intravitreal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07630649Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular DegenerationRecruitingPhase 22026-06-022031-0615Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
NCT07482176Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)RecruitingPhase 32026-03-162027-11-15534Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD
NCT06856577Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationActive not recruitingPhase 32025-02-282026-12-22311Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD
NCT05536973Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Active not recruitingPhase 22022-08-232024-08-2669Neovascular Age-related Macular Degeneration
NCT05607810Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)Active not recruiting2022-08-102031-0422Diabetic Macular Edema; Diabetic Retinopathy
NCT04645212Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Active not recruiting2020-12-142030-06-2623Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration
NCT04418427ADVM-022 Intravitreal Gene Therapy for DMECompletedPhase 22020-05-282022-11-2236Diabetic Macular Edema; Diabetic Retinopathy
NCT03748784ADVM-022 Intravitreal Gene Therapy for Wet AMDCompletedPhase 12018-11-142022-06-2230Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38152412Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.EClinicalMedicine2024cited by trial NCT03748784

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41490387Emerging solutions for neovascular age-related macular degeneration.Current opinion in ophthalmology2026name in abstract: ADVM-022
PMID 41688763AAV-based gene therapies for neovascular AMD.Gene therapy2026name in abstract: ADVM-022
PMID 39379521Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.Eye (London, England)2025name in abstract: ixo-vec
PMID 40092639Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes.Molecular therapy. Methods & clinical development2025name in title: ixo-vec
PMID 40293479Gene therapy in neovascular age related macular degeneration: an update.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025name in abstract: ixoberogene soroparvovec
PMID 40364236Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update.Journal of clinical medicine2025name in abstract: ADVM-022
PMID 40601510Gene Therapy in Age-related Macular Degeneration.International ophthalmology clinics2025name in abstract: ADVM-022
PMID 40689796A Semimechanistic Ocular Pharmacokinetic Model for ADVM-022 Gene Therapy Describing the Dose-Exposure Relationship in Monkeys and the Scaling to Human.Molecular pharmaceutics2025name in title: ADVM-022
PMID 38397064A New Generation of Gene Therapies as the Future of Wet AMD Treatment.International journal of molecular sciences2024name in abstract: ADVM-022
PMID 38927656Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.Genes2024name in abstract: ixoberogene soroparvovec
PMID 35017696Review of gene therapies for age-related macular degeneration.Eye (London, England)2022name in abstract: ADVM-022
PMID 33532145Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates.Translational vision science & technology2021name in title: ADVM-022
PMID 33835848Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2021name in title: ADVM-022
PMID 34188445Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.Drug design, development and therapy2021name in abstract: ADVM-022
PMID 32671137Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD.Molecular therapy. Methods & clinical development2020name in title: ADVM-022
PMID 30528929Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration.Molecular therapy : the journal of the American Society of Gene Therapy2019name in title: ADVM-022
PMID 31298960Innovative therapies for neovascular age-related macular degeneration.Expert opinion on pharmacotherapy2019name in abstract: ADVM-022

Notes

Intravitreal AAV.7m8 vector expressing aflibercept for neovascular AMD. Phase 1 OPTIC NCT03748784 (published), then the phase 3 ARTEMIS NCT06856577 and AQUARIUS NCT07482176. Formerly ADVM-022. `targets` empty: the transgene is a receptor-Fc fusion protein, not a human gene to be replaced.

How to cite

ixoberogene soroparvovec (AXP000258.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000258.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.